3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
5
Gastrointestinal
4
Thoracic
2
Breast
2
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Head and Neck Neoplasms
2095
Squamous Cell Carcinoma of Head and Neck
1649
Nasopharyngeal Carcinoma
517
Thyroid Neoplasms
477
Carcinoma, Non-Small-Cell Lung
435
Breast Neoplasms
314
Mouth Neoplasms
312
Neoplasms
309
Melanoma
299
Oropharyngeal Neoplasms
285
Colorectal Neoplasms
272
Lung Neoplasms
246
Carcinoma, Squamous Cell
239
Neoplasm Metastasis
235
Ovarian Neoplasms
226
Uterine Cervical Neoplasms
202
Stomach Neoplasms
195
Salivary Gland Neoplasms
192
Laryngeal Neoplasms
192
Nasopharyngeal Neoplasms
188
Carcinoma, Renal Cell
182
Esophageal Neoplasms
179
Pancreatic Neoplasms
176
Prostatic Neoplasms
157
Sarcoma
142
Urinary Bladder Neoplasms
135
Triple Negative Breast Neoplasms
134
Recurrence
127
Endometrial Neoplasms
123
Hypopharyngeal Neoplasms
121
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Tertiary Lymphoid Structures
×
Head & Neck
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled